2.66
price up icon5.14%   0.13
after-market Handel nachbörslich: 2.66
loading
Schlusskurs vom Vortag:
$2.53
Offen:
$2.5
24-Stunden-Volumen:
437.38K
Relative Volume:
1.04
Marktkapitalisierung:
$247.69M
Einnahmen:
$64.70M
Nettoeinkommen (Verlust:
$-123.43M
KGV:
-11.08
EPS:
-0.24
Netto-Cashflow:
$-95.23M
1W Leistung:
+8.57%
1M Leistung:
+1.92%
6M Leistung:
-7.32%
1J Leistung:
+8.57%
1-Tages-Spanne:
Value
$2.48
$2.66
1-Wochen-Bereich:
Value
$2.32
$2.66
52-Wochen-Spanne:
Value
$1.87
$4.27

Poseida Therapeutics Inc Stock (PSTX) Company Profile

Name
Firmenname
Poseida Therapeutics Inc
Name
Telefon
858-779-3100
Name
Adresse
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Name
Mitarbeiter
337
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PSTX's Discussions on Twitter

Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-04 Eingeleitet H.C. Wainwright Buy
2022-01-07 Eingeleitet Cantor Fitzgerald Overweight
2021-05-18 Eingeleitet BTIG Research Buy
2020-08-04 Eingeleitet BofA Securities Buy
2020-08-04 Eingeleitet Piper Sandler Overweight
2020-08-04 Eingeleitet William Blair Outperform
Alle ansehen

Poseida Therapeutics Inc Aktie (PSTX) Neueste Nachrichten

pulisher
05:21 AM

Poseida Therapeutics to present cancer cell therapy data at SITC, ASH - Investing.com

05:21 AM
pulisher
04:05 AM

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - PR Newswire

04:05 AM
pulisher
Nov 01, 2024

Poseida Therapeutics (STU:2RZ) Degree of Operating Leverage : -9.17 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024
pulisher
Oct 30, 2024

Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 30, 2024
pulisher
Oct 26, 2024

Poseida Therapeutics Receives Regenerative Medicine Advanced The - GuruFocus.com

Oct 26, 2024
pulisher
Oct 24, 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire

Oct 24, 2024
pulisher
Oct 19, 2024

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% - Simply Wall St

Oct 19, 2024
pulisher
Oct 18, 2024

Third development candidate nominated under Poseida and Roche’s allogeneic CAR T collaboration - BioWorld Online

Oct 18, 2024
pulisher
Oct 17, 2024

Poseida shares hold as analyst reiterates buy rating on MM study - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Nominates New Development Candidate Under Its Collaboration With Roche - Contract Pharma

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida advances with new CAR-T therapy candidate - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

Quarterly Metrics: Quick and Current Ratios for Poseida Therapeutics Inc (PSTX) - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World

Oct 15, 2024
pulisher
Oct 14, 2024

The Anatomy Of Astellas And Poseida's CAR-T Deal - In Vivo

Oct 14, 2024
pulisher
Oct 10, 2024

PSTXPoseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 10, 2024
pulisher
Oct 10, 2024

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™

Oct 10, 2024
pulisher
Oct 07, 2024

Ratio Examination: Poseida Therapeutics Inc (PSTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Poseida Therapeutics Inc (PSTX) deserves closer scrutiny - US Post News

Oct 07, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - IT News Online

Oct 03, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics (STU:2RZ) Long-Term Capital Lease Obli - GuruFocus.com

Oct 03, 2024
pulisher
Oct 03, 2024

Poseida Therapeutics (STU:2RZ) Net Change in Cash : €-18.49 Mil (TTM As of Jun. 2024) - GuruFocus.com

Oct 03, 2024
pulisher
Oct 03, 2024

Anchoring Your Portfolio: Is PSTX Stock a Safe Harbor? - The InvestChronicle

Oct 03, 2024
pulisher
Oct 02, 2024

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Renaissance Technologies LLC - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma - Genetic Engineering & Biotechnology News

Oct 02, 2024
pulisher
Oct 01, 2024

A new trading data show Poseida Therapeutics Inc (PSTX) is showing positive returns. - SETE News

Oct 01, 2024
pulisher
Oct 01, 2024

Poseida stock supported by strong data from P-BCMA-ALLO-1, says BTIG - Investing.com South Africa

Oct 01, 2024
pulisher
Sep 30, 2024

Piper Sandler maintains Overweight rating on Poseida Therapeutics shares - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida Therapeutics reveals promising trial results for myeloma treatment - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement - Seeking Alpha

Sep 30, 2024
pulisher
Sep 30, 2024

What technical indicators reveal about PSTX stock - US Post News

Sep 30, 2024
pulisher
Sep 30, 2024

Metric Analysis: Poseida Therapeutics Inc (PSTX)’s Key Ratios in the Limelight - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Piper Sandler maintains Overweight rating on Poseida Therapeutics shares By Investing.com - Investing.com UK

Sep 30, 2024
pulisher
Sep 28, 2024

Poseida reports high response in multiple myeloma trial - Investing.com India

Sep 28, 2024
pulisher
Sep 28, 2024

Poseida reports high response in multiple myeloma trial By Investing.com - Investing.com South Africa

Sep 28, 2024
pulisher
Sep 27, 2024

Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data - Marketscreener.com

Sep 27, 2024
pulisher
Sep 27, 2024

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - PR Newswire

Sep 27, 2024
pulisher
Sep 20, 2024

How did Poseida Therapeutics Inc (PSTX) fare last session? - US Post News

Sep 20, 2024
pulisher
Sep 20, 2024

Pivotree (CVE:PVT) Shares Up 3% - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Provident Financial Services And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency

Sep 19, 2024
pulisher
Sep 19, 2024

Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive™

Sep 19, 2024
pulisher
Sep 19, 2024

Altrius Capital Management Inc Buys 15,174 Shares of POSCO Holdings Inc. (NYSE:PKX) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Poseida Therapeutics Inc (PSTX) Stock: A Year of Market Fluctuations - The InvestChronicle

Sep 19, 2024
pulisher
Sep 18, 2024

Piper Sandler maintains Overweight rating on Opko Health shares on strong prospects - Investing.com Canada

Sep 18, 2024
pulisher
Sep 17, 2024

FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM - Myeloma Research News

Sep 17, 2024
pulisher
Sep 17, 2024

FDA grants RMAT status to Poseida’s P-BCMA-ALLO1 for relapsed/refractory multiple myeloma - World Pharmaceutical Frontiers

Sep 17, 2024
pulisher
Sep 17, 2024

FDA grants RMAT status to Poseida's multiple myeloma therapy By Investing.com - Investing.com Canada

Sep 17, 2024
pulisher
Sep 17, 2024

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1 - Pharmaceutical Technology

Sep 17, 2024

Finanzdaten der Poseida Therapeutics Inc-Aktie (PSTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):